Farther Finance Advisors LLC Boosts Stock Position in ADMA Biologics Inc $ADMA

Farther Finance Advisors LLC boosted its holdings in ADMA Biologics Inc (NASDAQ:ADMA) by 164.3% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 7,196 shares of the biotechnology company’s stock after purchasing an additional 4,473 shares during the period. Farther Finance Advisors LLC’s holdings in ADMA Biologics were worth $131,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of ADMA. GAMMA Investing LLC boosted its position in ADMA Biologics by 6,875.8% in the first quarter. GAMMA Investing LLC now owns 130,726 shares of the biotechnology company’s stock worth $2,594,000 after purchasing an additional 128,852 shares during the last quarter. First Citizens Bank & Trust Co. purchased a new position in shares of ADMA Biologics during the 1st quarter valued at $264,000. NorthCrest Asset Manangement LLC purchased a new position in shares of ADMA Biologics during the 1st quarter valued at $430,000. Janney Montgomery Scott LLC lifted its position in shares of ADMA Biologics by 7.4% during the 1st quarter. Janney Montgomery Scott LLC now owns 70,991 shares of the biotechnology company’s stock valued at $1,408,000 after buying an additional 4,865 shares during the last quarter. Finally, Envestnet Portfolio Solutions Inc. purchased a new position in shares of ADMA Biologics during the 1st quarter valued at $240,000. Hedge funds and other institutional investors own 75.68% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “buy (b-)” rating on shares of ADMA Biologics in a research report on Saturday, September 27th. One investment analyst has rated the stock with a Strong Buy rating and three have given a Buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $27.67.

ADMA Biologics Stock Performance

NASDAQ:ADMA opened at $14.66 on Friday. The business’s 50-day moving average price is $16.76 and its two-hundred day moving average price is $18.75. ADMA Biologics Inc has a twelve month low of $13.50 and a twelve month high of $25.67. The stock has a market cap of $3.50 billion, a P/E ratio of 17.05 and a beta of 0.47. The company has a quick ratio of 2.78, a current ratio of 5.33 and a debt-to-equity ratio of 0.21.

ADMA Biologics (NASDAQ:ADMA) last released its quarterly earnings results on Wednesday, August 6th. The biotechnology company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.14 by $0.01. ADMA Biologics had a return on equity of 41.01% and a net margin of 44.06%.The firm had revenue of $121.98 million for the quarter, compared to analysts’ expectations of $121.77 million. During the same quarter last year, the firm posted $0.13 EPS. The company’s revenue was up 13.8% compared to the same quarter last year. As a group, equities analysts predict that ADMA Biologics Inc will post 0.51 EPS for the current fiscal year.

About ADMA Biologics

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.